文献速递妇科

多塔利单抗治疗复发性错配修复缺陷子宫内膜癌的成本效果研究

Dostarlimab for recurrent mismatch repair-deficient endometrial cancer: A cost-effectiveness study.
PubMed 文献 · BJOG · 2022-11-21

该成本效果研究构建马尔可夫模型,模拟6000例一线化疗后进展的复发性错配修复缺陷(dMMR)子宫内膜癌患者,比较多塔利单抗、帕博利珠单抗与聚乙二醇脂质体多柔比星(PLD)的成本效果。以10万美元/QALY为支付意愿阈值,PLD最具成本效果,多塔利单抗的ICER为每QALY 331,913美元;多塔利单抗成本降至4905美元(降幅52%)时具成本效果,结论在多种敏感性分析中稳健。

要点

  • PLD总成本最低(55,732美元),多塔利单抗151,533美元,帕博利珠单抗154,597美元。
  • 以10万美元/QALY为阈值,多塔利单抗相对PLD的ICER为每QALY 331,913美元,不具成本效果。
  • 多塔利单抗成本降至4905美元(降幅52%)时具成本效果,结论在多种敏感性分析中稳健。

核心结论

  • 多塔利单抗较复发性dMMR子宫内膜癌其他治疗延长生存,但成本显著更高,成本降至每周期5489美元时具成本效果。

研究设计与样本

  • 成本效果研究,采用马尔可夫模型,假设队列为6000例一线化疗后进展的复发性dMMR子宫内膜癌女性,初始决策点为多塔利单抗、帕博利珠单抗或聚乙二醇脂质体多柔比星(PLD)治疗。

主要发现

  • PLD总成本最低为55,732美元,多塔利单抗为151,533美元,帕博利珠单抗为154,597美元。
  • 以10万美元/QALY为支付意愿阈值,多塔利单抗相对PLD的ICER为每QALY 331,913美元,帕博利珠单抗因扩展劣势(效果更差、成本更高)被排除。
  • 单因素敏感性分析中,多塔利单抗成本降至4905美元(降幅52%)时具成本效果,结果在多种敏感性分析中稳健。

关键数值与推荐

  • 支付意愿阈值为10万美元/QALY。
  • 多塔利单抗相对PLD的ICER为每QALY 331,913美元。
  • 多塔利单抗成本降至4905美元(降幅52%)时具成本效果;结论中提及成本降至每周期5489美元时具成本效果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with recurrent endometrial cancer treated with carboplatin and paclitaxel whose disease progresses have few effective treatment options. Based on promising clinical trial data, the anti-programmed cell death 1 (anti-PD-1) antibody dostarlimab was recently granted accelerated approval for endometrial cancer by the US Food and Drug Administration. We developed a decision model to examine the cost-effectiveness of dostarlimab for patients with progressive/recurrent deficient mismatch repair (dMMR) endometrial cancer whose disease has progressed with first-line chemotherapy. DESIGN: Cost-effectiveness study. POPULATION: Hypothetical cohort of 6000 women with progressive/recurrent dMMR endometrial cancer. METHODS: The initial decision point in the Markov model was treatment with dostarlimab, pembrolizumab or pegylated liposomal doxorubicin (PLD). Model probabilities, and cost and utility values were derived with assumptions drawn from published literature. Effectiveness was estimated as average quality-adjusted life years (QALYs) gained. One-way, two-way and probabilistic sensitivity analyses were performed to vary the assumptions across a range of plausible values. MAIN OUTCOME MEASURES: The primary outcome was the incremental cost-effectiveness ratio (ICER). RESULTS: Pegylated liposomal doxorubicin (PLD) was the least costly strategy, at $55,732, followed by dostarlimab ($151,533) and pembrolizumab ($154,597). Based on a willingness-to-pay threshold of $100,000/QALY, PLD was cost-effective compared with dostarlimab, with an ICER of $331,913 per QALY gained for dostarlimab, whereas pembrolizumab was ruled out by extended dominance (less effective, more costly), compared with dostarlimab. In one-way sensitivity analyses, dostarlimab was cost-effective when its cost was reduced to $4905 (52% reduction). These results were robust in a variety of sensitivity analyses. CONCLUSIONS: Dostarlimab is associated with greater survival compared with other treatments for women with recurrent dMMR endometrial cancer. Although the agent is substantially more costly, dostarlimab became cost-effective when its cost was reduced to $5489 per cycle.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Dioun S, Chen L, Melamed A, et al. Dostarlimab for recurrent mismatch repair-deficient endometrial cancer: A cost-effectiveness study. BJOG. 2022. PMID: 36330672. doi:10.1111/1471-0528.17338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。